Zacks Research Cuts Earnings Estimates for Gilead Sciences

Gilead Sciences, Inc. (NASDAQ:GILD) – Equities research analysts at Zacks Research cut their Q1 2028 earnings estimates for Gilead Sciences in a note issued to investors on Thursday, October 1st. Zacks Research analyst Team now anticipates that the biopharmaceutical company will post earnings of $2.14 per share for the quarter, down from their prior forecast of $2.15. Zacks Research has a “Hold” rating on the stock. The consensus estimate for Gilead Sciences’ current full-year earnings is ($0.48) per share.

Other equities analysts have also issued research reports about the company. Weiss Ratings raised Gilead Sciences from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, September 14th. HSBC lifted their price target on Gilead Sciences from $155.00 to $175.00 and gave the stock a “buy” rating in a report on Thursday, September 10th. Wall Street Zen raised Gilead Sciences from a “hold” rating to a “buy” rating in a research report on Saturday, September 19th. Royal Bank Of Canada increased their price objective on Gilead Sciences from $120.00 to $123.00 and gave the company a “sector perform” rating in a report on Wednesday, August 5th. Finally, Morgan Stanley cut their target price on Gilead Sciences from $166.00 to $165.00 and set an “overweight” rating on the stock in a research report on Monday, July 27th. Twenty-three analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat, Gilead Sciences presently has an average rating of “Moderate Buy” and an average price target of $158.78.

Gilead Sciences Price Performance

Gilead Sciences stock opened at $144.23 on Monday. The stock has a market cap of $178.84 billion, a P/E ratio of -54.02 and a beta of 0.31. The company has a fifty day simple moving average of $144.11 and a 200-day simple moving average of $136.51. Gilead Sciences has a 12-month low of $112.82 and a 12-month high of $157.29. The company has a current ratio of 1.27, a quick ratio of 1.09 and a debt-to-equity ratio of 2.03.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) EPS for the quarter, topping the consensus estimate of ($7.25) by $0.50. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The company had revenue of $7.80 billion during the quarter, compared to analysts’ expectations of $7.40 billion. During the same quarter in the previous year, the business posted $2.01 EPS. The firm’s revenue was up 10.6% on a year-over-year basis.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 29th. Investors of record on Tuesday, September 15th were given a $0.82 dividend. The ex-dividend date of this dividend was Tuesday, September 15th. This represents a $3.28 dividend on an annualized basis and a yield of 2.3%. Gilead Sciences’s payout ratio is -122.85%.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, CEO Daniel O’Day sold 15,000 shares of the company’s stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $147.90, for a total value of $2,218,500.00. Following the completion of the transaction, the chief executive officer owned 566,683 shares in the company, valued at $83,812,415.70. This represents a 2.58% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jeffrey Bluestone sold 5,000 shares of the firm’s stock in a transaction dated Thursday, August 20th. The stock was sold at an average price of $145.02, for a total value of $725,100.00. Following the transaction, the director directly owned 10,066 shares in the company, valued at approximately $1,459,771.32. The trade was a 33.19% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 105,000 shares of company stock valued at $14,940,540 over the last quarter. 0.30% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new position in shares of Gilead Sciences during the second quarter worth approximately $15,393,785,000. State Street Corp raised its position in Gilead Sciences by 2.3% in the 2nd quarter. State Street Corp now owns 61,216,552 shares of the biopharmaceutical company’s stock valued at $7,734,099,000 after purchasing an additional 1,357,967 shares during the last quarter. Invesco Ltd. raised its position in Gilead Sciences by 2.9% in the 4th quarter. Invesco Ltd. now owns 15,584,341 shares of the biopharmaceutical company’s stock valued at $1,912,822,000 after purchasing an additional 444,660 shares during the last quarter. Amundi boosted its stake in Gilead Sciences by 10.7% during the 1st quarter. Amundi now owns 10,539,111 shares of the biopharmaceutical company’s stock worth $1,468,836,000 after purchasing an additional 1,018,976 shares during the period. Finally, Legal & General Group Plc acquired a new stake in Gilead Sciences during the 2nd quarter worth $1,316,606,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc (NASDAQ: GILD) is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. Its research and commercial activities focus primarily on virology, including HIV, hepatitis B and hepatitis C, as well as oncology, inflammation and other areas of significant unmet medical need.

Gilead’s portfolio includes HIV treatments such as Biktarvy, Descovy, Genvoya and Sunlenca; hepatitis therapies including Epclusa, Harvoni and Vemlidy; and Veklury (remdesivir), an antiviral used to treat COVID-19 in certain patients.